Skip to Content

Publications Search - Abstract View

Title: Increased risk of second primary cancers after a diagnosis of melanoma.
Authors: Bradford PT,  Freedman DM,  Goldstein AM,  Tucker MA
Journal: Arch Dermatol
Date: 2010 Mar
Branches: GEB, REB
PubMed ID: 20231496
PMC ID: PMC3076705
Abstract: OBJECTIVE: To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma. DESIGN: Population-based registry study. SETTING: We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006. PARTICIPANTS: We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis. RESULTS: Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively). CONCLUSIONS: Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.